{
  "docId": "019de071-eb84-776b-8e7d-ce40a476afec",
  "docSlug": "ee62a94395a2a2b10c5eb93465b3bf02",
  "documentTitle": "Kymera | Investor Day Presentation Deck | 105 slides",
  "authorId": "kymera",
  "authorName": "Kymera",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 52,
  "pageCount": 105,
  "prevPage": 51,
  "nextPage": 53,
  "slideType": "key_takeaways",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "Includes potency metrics (DC50, EC50) and dose-response curves for multiple cell lines.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-eb84-776b-8e7d-ce40a476afec/52",
  "deckHref": "/decks/019de071-eb84-776b-8e7d-ce40a476afec",
  "deckJsonHref": "/decks/019de071-eb84-776b-8e7d-ce40a476afec.json",
  "deckAnchorHref": "/decks/019de071-eb84-776b-8e7d-ce40a476afec#slide-52",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.35,
        "y": 0.18
      },
      "kind": "callout",
      "text": "KT-413 IRAK4 DC50 = 6 nM Ikaros DC50 = 2 nM Aiolos DC50 = 2 nM OCI-Ly-10 (MYD88MT DLBCL) EC50 = 1 nM",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "23a12a3c-14bc-466e-af53-a19c43325c0a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.65,
        "y": 0.18
      },
      "kind": "chart",
      "text": "Dose-response curves for IRAK4, Ikaros, Aiolos degradation and CTG growth inhibition",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7aacb1f6-fb9d-4c5b-9ea8-1e2b9595c49f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.35,
        "y": 0.55
      },
      "kind": "chart",
      "text": "OCI-Ly10 (MYD88L265P) dose-response comparison",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9fd47839-8140-461d-8253-6992c8eb6c95",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.65,
        "y": 0.55
      },
      "kind": "chart",
      "text": "SUDHL2 (MYD88S222R) dose-response comparison",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ea417888-43eb-47a0-8db1-17dcb757a7b5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.05,
        "y": 0.55
      },
      "kind": "list",
      "text": "KT-413 is more active in MYD88MT DLBCL cells than the clinically active IMiD, CC-220, and IRAK4-selective degrader, KTX-545",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6445d306-1c1e-4cd3-b700-b099e8d1b0a2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "list",
      "text": "KT-413 selectively degrades both IRAK4 and IMiD substrates which leads to a profound antitumor effect in vitro and in vivo",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f92837f7-2795-402c-a77d-5222af7c7423",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "KT-413 is a Potent Degrader of IRAK4 and IMiD Substrates with Potent Activity in MYD88MT Cell lines",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9fef9514-722d-4c0d-97b4-f104efe29834",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "e389361e-9c80-4434-babf-9d33f969ee2b",
      "evidence": "chart/line: Dose-response curves for IRAK4, Ikaros, Aiolos degradation and CTG growth inhibition",
      "confidence": 0.7
    },
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "f89f208d-1e92-467e-8008-4c00f46a390f",
      "evidence": "list/bullet: KT-413 is more active in MYD88MT DLBCL cells than the clinically active IMiD, CC-220, and IRAK4-selective degrader, KTX-545",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}